BioAdaptives, Inc. (BDPT) stock
BDPTOTCPharmaceutical PreparationsFiscal year ends December 31
$0.00−0.00 (-5.56%)
Close on Oct 19, 2026Market cap $478.03KP/E –Yield –
BioAdaptives net income
Net income is the profit left for shareholders after every expense, interest and tax.
BioAdaptives's net income for the twelve months ending Jun 30, 2026 was -$1.16M. For fiscal 2025 it was -$1.56M. The highest annual figure on record is -$227.43K in fiscal 2015.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.56M | – |
| FY2024 | Dec 31, 2024 | -$899.16K | – |
| FY2023 | Dec 31, 2023 | -$712.47K | – |
| FY2022 | Dec 31, 2022 | -$895.57K | – |
| FY2021 | Dec 31, 2021 | -$1.05M | – |
| FY2020 | Dec 31, 2020 | -$847.24K | – |
| FY2019 | Dec 31, 2019 | -$238.93K | – |
| FY2018 | Dec 31, 2018 | -$1.41M | – |
| FY2015 | Dec 31, 2015 | -$227.43K | – |
| FY2014 | Dec 31, 2014 | -$2.58M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $150.09K | – |
| Q1 FY2026 | Mar 31, 2026 | -$111.09K | – |
| Q4 FY2025 | Dec 31, 2025 | -$823.35K | – |
| Q3 FY2025 | Sep 30, 2025 | -$379.50K | – |
| Q2 FY2025 | Jun 30, 2025 | -$157.91K | – |
| Q1 FY2025 | Mar 31, 2025 | -$197.14K | – |
| Q4 FY2024 | Dec 31, 2024 | -$371.79K | – |
| Q3 FY2024 | Sep 30, 2024 | -$37.65K | – |
| Q2 FY2024 | Jun 30, 2024 | -$183.02K | – |
| Q1 FY2024 | Mar 31, 2024 | -$306.71K | – |
| Q4 FY2023 | Dec 31, 2023 | -$268.30K | – |
| Q3 FY2023 | Sep 30, 2023 | -$13.06K | – |
| Q2 FY2023 | Jun 30, 2023 | -$143.92K | – |
| Q1 FY2023 | Mar 31, 2023 | -$287.19K | – |
| Q4 FY2022 | Dec 31, 2022 | -$28.28K | – |
| Q3 FY2022 | Sep 30, 2022 | -$276.33K | – |
| Q2 FY2022 | Jun 30, 2022 | -$223.84K | – |
| Q1 FY2022 | Mar 31, 2022 | -$367.13K | – |
| Q4 FY2021 | Dec 31, 2021 | -$214.28K | – |
| Q3 FY2021 | Sep 30, 2021 | -$34.52K | – |
| Q2 FY2021 | Jun 30, 2021 | -$309.25K | – |
| Q1 FY2021 | Mar 31, 2021 | -$491.90K | – |
| Q4 FY2020 | Dec 31, 2020 | -$165.42K | – |
| Q3 FY2020 | Sep 30, 2020 | -$13.46K | – |
| Q2 FY2020 | Jun 30, 2020 | -$430.44K | – |
| Q1 FY2020 | Mar 31, 2020 | -$237.92K | -357.4% |
| Q4 FY2019 | Dec 31, 2019 | -$96.60K | – |
| Q3 FY2019 | Sep 30, 2019 | -$54.91K | – |
| Q2 FY2019 | Jun 30, 2019 | -$179.87K | – |
| Q1 FY2019 | Mar 31, 2019 | $92.45K | – |
| Q4 FY2018 | Dec 31, 2018 | -$336.19K | – |
| Q3 FY2018 | Sep 30, 2018 | -$648.60K | – |
| Q2 FY2018 | Jun 30, 2018 | -$412.78K | – |
| Q1 FY2018 | Mar 31, 2018 | -$9.10K | – |
| Q3 FY2016 | Sep 30, 2016 | -$26.31K | – |
| Q2 FY2016 | Jun 30, 2016 | -$33.21K | – |
| Q1 FY2016 | Mar 31, 2016 | -$80.92K | – |
| Q4 FY2015 | Dec 31, 2015 | -$48.51K | – |
| Q3 FY2015 | Sep 30, 2015 | -$40.14K | – |
See a number that looks wrong?